Skip to main content

Serotonin and GABA-B receptors in anxiety : from developmental risk factors to treatment

Objective

GABAergic and serotoninergic systems are key players in the control of anxiety states but the precise bases for their action has remained elusive. New findings, brought about by members of this consortium, are radically changing our views on the neurobiological action of these two transmitters and will be the focus of the present proposal. The first original dimension is the discovery of a developmental role of serotonin (5-HT) in the genesis of anxiety disorders, and the finding of interactions between 5-HT-related genes and environmental risk factors. The second new dimension is the discovery that metabotropic GABA-B receptors play a critical role in mediating the anxiolytic effects of GABA, a starting point for the conception and design of novel therapeutic approaches. Finally, recent evidence point to strong reciprocal interactions between the two systems. In this proposal , researchers that are at the forefront of these research domains will build on and extend these promising new findings. The project associates specialists of development, neuronal plasticity, neurobehaviour, neuropharmacology and mouse genetics. The consortium will explore the neuronal circuits mediating the developmental effects of 5-HT by using existing models and by creating new models for site- and time-specific invalidation of 5-HT related genes (Tph2, pet1,VMAT2,5-HT1A-R), focusing on the hippocampus, amygdala and raphe nuclei. They will explore the role of GABA-B receptors in anxiety and the interaction of these receptors with the 5-HT system. The developmental effects of GABA-B receptors and a new generation of GABA-B modulators that produce anxiolytic effects in animal models will be explored. Finally they will investigate how exposure to adverse environments interacts with 5-HT-genes and GABA-B receptor genes to produce anxiety phenotypes. The proposal will bring new knowledge on the neurobiological basis of anxiety, and open up novel therapeutic approaches in anxiety disorders

Field of science

  • /medical and health sciences/clinical medicine/psychiatry/anxiety disorders

Call for proposal

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 903 038
Administrative Contact
Mihaja Auguste (Ms.)

Participants (5)

EUROPEAN MOLECULAR BIOLOGY LABORATORY
Germany
EU contribution
€ 401 200
Address
Meyerhofstrasse 1
69117 Heidelberg
Activity type
Research Organisations
Administrative Contact
Pascale Beudin (Ms.)
UNIVERSITAT BASEL
Switzerland
EU contribution
€ 400 000
Address
Petersplatz 1
4051 Basel
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Eva Kramer (Ms.)
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
Ireland
EU contribution
€ 400 000
Address
Western Road
T12 YN60 Cork
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mary Cusack (Ms.)
UNIVERSIDAD PABLO DE OLAVIDE
Spain
EU contribution
€ 337 340
Address
Carretera De Utrera Km 1
41013 Sevilla
Activity type
Higher or Secondary Education Establishments
Administrative Contact
José Manuel Jiménez Cañete (Mr.)
ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT
Germany
EU contribution
€ 400 000
Address
Square J 5
68159 Mannheim
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Simone Fuchs (Ms.)